BioNxt Solutions (CSE: BNXT; OTCQB: BNXTF; FSE: BXT) has announced that it has completed a large-mass porcine comparative pharmacokinetic study and received preliminary results evaluating the absorption of cladribine over time, comparing its proprietary swallow-free, orally dissolving film (ODF) formulation with the reference tablet for the treatment of Multiple Sclerosis.
According to BioNxt, the study outcome was successful and supports superior bioavailability for the company’s cladribine ODF formulation under the study conditions.
In a statement, Hugh Rogers, CEO of BioNxt, commented, “We are extremely encouraged by the successful outcome of this study. The results reinforce our belief that sublingual ODF delivery can materially improve the efficiency of cladribine administration and may ultimately support better patient tolerability and adoption. We look forward to sharing additional details once our complete internal analysis is finalized. The data from this study is critical to optimize the dosing parameters in our upcoming human bioequivalence study.”
